SEARCH:   Advanced

Blood, 15 June 2005, Vol. 105, No. 12, pp. 4878-4884. Prepublished online as a Blood First Edition Paper on February 24, 2005; DOI 10.1182/blood-2004-12-4825. This Article Full Text (PDF) Supplemental Table All Versions of this Article: 2004-12-4825v1 105/12/4878    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hsu, K. C Articles by Dupont, B. Search for Related Content PubMed PubMed Citation Articles by Hsu, K. C Articles by Dupont, B. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 20, 2004 Accepted February 10, 2005 Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes Katharine C Hsu*, Carolyn A Keever-Taylor, Andrew Wilton, Clara Pinto, Glenn Heller, Knarik Arkun, Richard J O'Reilly, Mary M Horowitz, and Bo Dupont Allogeneic Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Bone Marrow Transplant Program, Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin, Milwaukee, WI, USA Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Immunology Program, Sloan-Kettering Institute for Cancer Research, New York, NY, USA * Corresponding author; email: hsuk{at}mskcc.org. Inhibitory killer Ig-like receptors (KIR) recognize HLA-C and -B epitopes on target cells, thereby regulating natural killer (NK) cell activity. In 178 patients receiving T-cell depleted HLA-identical sibling transplants for CML, ALL, AML, and MDS, analysis of donor KIR genotype with HLA genotype demonstrated that 62.9% of the patients lacked an HLA ligand for donor inhibitory KIR. Lack of HLA ligand for donor inhibitory KIR ("missing KIR ligand") had no effect on disease-free survival (DFS), overall survival (OS), or relapse in patients receiving transplants for CML and ALL. There was, however, a significant missing KIR ligand effect in AML and MDS on DFS (p=0.014, HR 0.53, 95% CI 0.28-0.88) and OS (p=0.03, HR 0.53, 95% CI 0.3-0.93). Incidence of relapse was also lower in AML and MDS patients lacking HLA ligand for donor inhibitory KIR (p=0.04, HR 0.41, 95% CI 0.18-0.97). AML and MDS patients lacking two HLA ligands for donor inhibitory KIR had the highest DFS (p=0.002) and OS (p=0.003). There was no significant contribution of donor activating KIR to transplant outcome in these patients. These data indicate that absence of class I ligand in the recipient for donor inhibitory KIR can be a prognostic factor for transplant outcome in HLA-identical sibling transplants, and that lack of either HLA-C or -B ligands for donor inhibitory KIR can contribute to improved outcome in AML and MDS. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Lundqvist, H. Yokoyama, A. Smith, M. Berg, and R. Childs Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells Blood, June 11, 2009; 113(24): 6120 - 6127. [Abstract] [Full Text] [PDF] H. Fujisaki, H. Kakuda, N. Shimasaki, C. Imai, J. Ma, T. Lockey, P. Eldridge, W. H. Leung, and D. Campana Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy Cancer Res., May 1, 2009; 69(9): 4010 - 4017. [Abstract] [Full Text] [PDF] J. Yu, J. M. Venstrom, X.-R. Liu, J. Pring, R. S. Hasan, R. J. O'Reilly, and K. C. Hsu Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation Blood, April 16, 2009; 113(16): 3875 - 3884. [Abstract] [Full Text] [PDF] S. Cooley, E. Trachtenberg, T. L. Bergemann, K. Saeteurn, J. Klein, C. T. Le, S. G. E. Marsh, L. A. Guethlein, P. Parham, J. S. Miller, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia Blood, January 15, 2009; 113(3): 726 - 732. [Abstract] [Full Text] [PDF] K. Iizuka, A. A. Scalzo, H. Xian, and W. M. Yokoyama Regulation of the NK Cell Alloreactivity to Bone Marrow Cells by the Combination of the Host NK Gene Complex and MHC Haplotypes J. Immunol., March 1, 2008; 180(5): 3260 - 3267. [Abstract] [Full Text] [PDF] S. Kim, J. B. Sunwoo, L. Yang, T. Choi, Y.-J. Song, A. R. French, A. Vlahiotis, J. F. Piccirillo, M. Cella, M. Colonna, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency PNAS, February 26, 2008; 105(8): 3053 - 3058. [Abstract] [Full Text] [PDF] J. Yu, G. Heller, J. Chewning, S. Kim, W. M. Yokoyama, and K. C. Hsu Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands J. Immunol., November 1, 2007; 179(9): 5977 - 5989. [Abstract] [Full Text] [PDF] J. H. Chewning, C. N. Gudme, K. C. Hsu, A. Selvakumar, and B. Dupont KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro J. Immunol., July 15, 2007; 179(2): 854 - 868. [Abstract] [Full Text] [PDF] L. Ruggeri, A. Mancusi, M. Capanni, E. Urbani, A. Carotti, T. Aloisi, M. Stern, D. Pende, K. Perruccio, E. Burchielli, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood, July 1, 2007; 110(1): 433 - 440. [Abstract] [Full Text] [PDF] J. S. Miller, S. Cooley, P. Parham, S. S. Farag, M. R. Verneris, K. L. McQueen, L. A. Guethlein, E. A. Trachtenberg, M. Haagenson, M. M. Horowitz, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT Blood, June 1, 2007; 109(11): 5058 - 5061. [Abstract] [Full Text] [PDF] A. Lundqvist, J. Philip McCoy, L. Samsel, and R. Childs Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors Blood, April 15, 2007; 109(8): 3603 - 3606. [Abstract] [Full Text] [PDF] J. C. Fischer, H. Ottinger, S. Ferencik, M. Sribar, M. Punzel, D. W. Beelen, M. A. Schwan, H. Grosse-Wilde, P. Wernet, and M. Uhrberg Relevance of C1 and C2 Epitopes for Hemopoietic Stem Cell Transplantation: Role for Sequential Acquisition of HLA-C-Specific Inhibitory Killer Ig-Like Receptor J. Immunol., March 15, 2007; 178(6): 3918 - 3923. [Abstract] [Full Text] [PDF] A. Mullally and J. Ritz Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation Blood, February 15, 2007; 109(4): 1355 - 1362. [Abstract] [Full Text] [PDF] J. H. Park, A. J. Yee, T. R. Spitzer, S. L. Saidman, D. T. Ting, A. Pannone, J. Reid, S. McAfee, and B. R. Dey KIR Ligand Incompatibility in HLA-Identical Sibling Nonmyeloablative Hematopoietic Stem Cell Transplantation for Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 5371 - 5371. [Abstract] [PDF] C. J. VandenBussche, S. Dakshanamurthy, P. E. Posch, and C. K. Hurley A Single Polymorphism Disrupts the Killer Ig-Like Receptor 2DL2/2DL3 D1 Domain J. Immunol., October 15, 2006; 177(8): 5347 - 5357. [Abstract] [Full Text] [PDF] A. P. Williams, A. R. Bateman, and S. I. Khakoo HANGING IN THE BALANCE: KIR and Their Role in Disease Mol. Interv., August 1, 2005; 5(4): 226 - 240. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020